Patient P-01341

Synthetic patientNBL-101 · Day 97 · 65–74 · M · baseline S14Steering view · 3D Open companion preview

Therapy response

Improving

Tolerance

Deteriorating

GI state

Stable

Inflammatory state

Deteriorating

Nutritional resilience

Declining

Discontinuation risk

64%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 31 NP-02 recommended — Dietary Support Protocol NP-02
Day 32 Patient accepted — Started NP-02 in the companion
Day 42 GI symptom burden −14% vs expected — Dietary Support Protocol NP-02
Day 48 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 48 Tolerance state changed — Unstable → Improving
Day 50 GI-04 recommended — GI Support Protocol GI-04
Day 51 Patient accepted — Started GI-04 in the companion
Day 59 GI symptom burden −37% vs expected — GI Support Protocol GI-04
Day 65 Tolerance state changed — Unstable → Improving
Day 67 ME-01 recommended — Monitoring Escalation ME-01
Day 68 Patient accepted — Started ME-01 in the companion
Day 71 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 48.

Primary contributors, last 14 days

Toxicity+17
Nutritional resilience-6
Treatment adherence+6
GI instability+4
Inflammatory activity+4

What helped?

Dietary Support Protocol NP-02Day 31
Result: symptom burden −14%
GI Support Protocol GI-04Day 50
Result: symptom burden −37%
Monitoring Escalation ME-01Day 67
Result: deterioration detected before clinical escalation

LIFE OS recommendation

Supportive Compound SC-12

71%

probability of meaningful tolerance improvement

284 similar trajectories
81% showed improvement
median effect visible after 6 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden

Companion

46.3/100

worsening · +3.4 vs previous 14 d

Toxicity

Blood

44.1/100

worsening · +5.0 vs previous 14 d

Sleep quality

Wearable

19.9/100

worsening · -5.5 vs previous 14 d

Energy level

Daily log

4/10

worsening · -0.5 vs previous 14 d

Stress level

Daily log

7.3/10

worsening · +0.5 vs previous 14 d

Steps

Wearable

2,401

worsening · -425 vs previous 14 d

Adherence

Companion

59.5 %

worsening · -8.5 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards restoration · 37 from the failing basin, 50 from restoration.

Would help

SC-12 Supportive Compound
76% improved among 51 similar · onset 6 d · confidence 73%
CR-01 Clinician Review
100% improved among 8 similar · onset 5 d · confidence 73%

Would not help

Keep simple carbs low
GI +5.3 next day on high-intake days · n 23
Keep fat low
GI +4.9 next day on high-intake days · n 20

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Simple carbohydrates
+5.3detractor · 95%
Dietary fat load
+4.9detractor · 95%
Spicy / capsaicin
+1.9no signal · 44%
Alcohol
+0.2no signal · 15%
Histamine load
-0.1no signal · 15%
Insoluble fibre
0no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Inflammatory signalling ↑85
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 49
- WearableHRV 19 ms, trending down
Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 26/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Autonomic recovery ↓65
- WearableResting HR 73 bpm
- Wearable2,401 steps/day
- WearableShort sleep window
Mucosal barrier integrity ↓30
- Daily logGI symptom score 46 and rising
- WearableSleep 5.9 h, below personal baseline
Drug metabolism and exposure ↑20
- BloodToxicity index 44

DNA

Fictional pharmacogenomic panel

IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 2 · butyrate capacity 26/100

Akkermansia muciniphilaNormal
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumLow
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 21 ms
Sleep: 6.7 h
Steps: 3,853
Resting HR: 72 bpm

Daily log: GI score 46, nutritional resilience 43, adherence 60.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01819	24%	S13	—	—	72
P-01604	23%	S01	—	—	71
P-01386	23%	S13	—	—	70
P-01699	27%	S04	GI-04	improved	69
P-01508	24%	S18	—	—	68
P-01509	23%	S17	—	—	68
P-01875	24%	S11	—	—	67
P-01817	24%	S14	—	—	67
P-01877	25%	S01	CR-01	improved	67
P-01629	25%	S19	—	—	66
P-01714	27%	S14	GI-04	improved	66
P-01858	26%	S14	NP-02	improved	65